Our ultimate goal is to promote the move away from one-size-fits-all therapies to improve patient outcome through treatment stratification and tailoring. Despite advances in precision medicine diagnostics, there are still major opportunities to improve individualized patient care throughout the entire health care value chain, spanning from preclinical studies in drug discovery through to the design of precision diagnostics.
Research in my team focuses on challenges central to these fields, namely developing technologies and disease models that enable direct measurement of patient response to treatment ex vivo and investigation of the molecular determinants of drug response. Such methods and model systems are critical to improve the study of disease biology, identify and validate new drug targets, correctly prioritize drug candidates for clinical trials, uncover potential biomarkers for future patient stratification and have even recently been used to successfully as diagnostics to match patients to effective treatments.
Our translational research group and surrounding team of clinicians and experts has two major themes as described below united by the main goal of investigating drug response and biomarkers in primary patient cells and other near-patient models of disease.